Slovakia - Slovak - ŠÚKL (Štátny ústav pre kontrolu liečiv)

orion corporation, fínsko - budezonid - 14 - bronchodilatantia, antiasthmatica

Slovakia - Slovak - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sanofi-aventis slovakia s.r.o., slovensko - ambroxol - 52 - expectorantia, mucolytica

Slovakia - Slovak - ŠÚKL (Štátny ústav pre kontrolu liečiv)

orion corporation, fínsko - risperidón - 68 - antipsychotica (neuroleptica)

Slovakia - Slovak - ŠÚKL (Štátny ústav pre kontrolu liečiv)

orion corporation, fínsko - metotrexát - 44 - cytostatica

Slovakia - Slovak - ŠÚKL (Štátny ústav pre kontrolu liečiv)

orion corporation, fínsko - metotrexát - 44 - cytostatica

Kesatuan Eropah - Slovak - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinúria, paroxysmálna - selektívne imunosupresíva - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Slovakia - Slovak - ŠÚKL (Štátny ústav pre kontrolu liečiv)

carestream health inc. 150 verona street 14608 rochester, new york spojené štáty americké -

Slovakia - Slovak - ŠÚKL (Štátny ústav pre kontrolu liečiv)

orion corporation, fínsko - salmeterol a flutikazón - 14 - bronchodilatantia, antiasthmatica

Slovakia - Slovak - ŠÚKL (Štátny ústav pre kontrolu liečiv)

orion corporation, fínsko - salmeterol a flutikazón - 14 - bronchodilatantia, antiasthmatica

Slovakia - Slovak - ŠÚKL (Štátny ústav pre kontrolu liečiv)

orion corporation, fínsko - metotrexát - 29 - antirheumatica, antiphlogistica, antiuratica